Ultragenyx is trading 4.1% up at $25.57 after reporting record second-quarter revenue that significantly exceeded Wall Street expectations.
- The company posted Q2 2026 revenue of $214 million, well above the $182.5 million analyst consensus.
- Management reaffirmed its full-year 2026 guidance and highlighted a pipeline entering a transformative period.
- Positive momentum in the broader biotech sector and U.S. indices provided additional tailwinds for the post-earnings move.